Greg Zante sold $10M of VKTX
Chief Financial Officer at Viking Therapeutics, Inc.. 131,687 shares at an average of $76.61, traded Oct 28, 2024, filed Oct 28, 2024.
Score components
- +22RoleCFO
- +25Trade size$10.1M at market
- +10Share of holdings soldSold 47% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -26.9%, 3m -55.1%, 6m -65.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-117885, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +12,750 | $7.77 | $99k | 199,802 | Oct 28, 2024 |
| Oct 28, 2024 | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +4,251 | $4.68 | $20k | 204,053 | Oct 28, 2024 |
| Oct 28, 2024 | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +26,000 | $5.80 | $151k | 230,053 | Oct 28, 2024 |
| Oct 28, 2024 | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +51,000 | $8.52 | $435k | 281,053 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -49,672 | $74.56 | $3.7M | 231,381 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -18,620 | $75.79 | $1.4M | 212,761 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -9,265 | $76.94 | $713k | 203,496 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -23,082 | $77.68 | $1.8M | 180,414 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -15,825 | $78.69 | $1.2M | 164,589 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -6,050 | $79.78 | $483k | 158,539 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -7,967 | $80.65 | $643k | 150,572 | Oct 28, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -1,206 | $81.44 | $98k | 149,366 | Oct 28, 2024 |
| Oct 28, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,750 | $0.00 | $0 | 0 | Oct 28, 2024 |
| Oct 28, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,251 | $0.00 | $0 | 0 | Oct 28, 2024 |
| Oct 28, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -26,000 | $0.00 | $0 | 0 | Oct 28, 2024 |
| Oct 28, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -51,000 | $0.00 | $0 | 153,000 | Oct 28, 2024 |
Related signals
Other insiders at Viking Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | Viking Therapeutics, Inc. | Brian Lian President & CEO | $4.9M 148,517 shares | -5% | |
| 55Moderate | Viking Therapeutics, Inc. | Marianna Mancini Chief Operating Officer | $610k 18,217 shares | -4% | |
| 58Moderate | Viking Therapeutics, Inc. | Greg Zante Chief Financial Officer | $710k 21,217 shares | -9% | |
| 38Weak | VKTXbuy Viking Therapeutics, Inc. | Neil William Aubuchon Chief Commercial Officer | $150k 4,475 shares | - | |
| 39Weak | Viking Therapeutics, Inc. | Matthew W Foehr director | $562k 16,000 shares | -11% | |
| 65Notable | Viking Therapeutics, Inc. | Brian Lian President & CEO | $7.7M 233,409 shares | -9% | |
| 65Notable | Viking Therapeutics, Inc. | Marianna Mancini Chief Operating Officer | $1.9M 57,661 shares | -12% | |
| 67Notable | Viking Therapeutics, Inc. | Greg Zante Chief Financial Officer | $1.9M 57,661 shares | -23% | |
| 65Notable | Viking Therapeutics, Inc. | Brian Lian President & CEO | $1.4M 38,989 shares | -2% | |
| 47Moderate | Viking Therapeutics, Inc. | Marianna Mancini Chief Operating Officer | $216k 6,185 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.